Dr Pietanza presents, at a press conference at ECC 2015, data from a phase I study that assessed the safety, activity and durability of response to the investigational agent rovalpituzumab tesirine (Rova-T) in patients with small cell lung cancer (SCLC).

Rova-T is an antibody drug conjugate consisting of a humanised monoclonal antibody, a dipeptide linker and the active chemotherapy pyrrolbenzodiazepine. It is a first-in-class agent that targets the delta-like 3 (DLL3) which is overexpressed by tumours in about two-thirds of patients with SCLC.

In the trial, good response rates were seen across a range of patients with relapsed and refractory disease, which is the first time a targeted therapy has shown promise in this setting.

Read the news story or watch the video interview for more.